Summary
The EGFR-mutant NSCLC treatment market was valued at USD 6.6 billion in 2025 and is projected to grow at a 7.3% CAGR over the next decade, driven largely by the emergence of targeted biologics and ADCs.
The recent approval of Dato-DXd marks a major milestone and is expected to accelerate the adoption of ADC-based therapies, while multiple late-stage candidates continue to advance aggressively through clinical development.
Key players shaping this landscape include Merck and Kelun-Biotech’s sacituzumab tirumotecan, Pfizer’s PF-08046054, CSPC Pharmaceutical’s SYS6010, Bristol Myers Squibb’s izalontamab brengitecan, AbbVie’s telisotuzumab adizutecan, Da...
